Clinical governance is a shared responsibility to ensure all patients receive the best care. Pharmacists, members of the treating team and managers share the common goal of optimising patient care. Pharmacists share accountability for the care delivered, the equitable use of resources and building a positive workplace culture. Pharmacists are ideally placed and skilled to minimise the risk to patients when reviewing, compounding and/or dispensing anticancer medicines.

Clinical governance is a shared responsibility to ensure all patients receive the best care. Nurses, other members of the treating team and managers share the common goal of optimising patient care. Nurses share accountability for the care delivered, the equitable use of resources and building a positive workplace culture.

Clinical governance is a shared responsibility to ensure all patients receive the best care. Medical oncologists, haematologists, other members of the treating team and managers share the common goal of optimising patient care. Medical oncologists and haematologists share accountability for the care delivered, the equitable use of resources and building a positive workplace culture.

Clinical governance is a shared responsibility to ensure all patients receive the best care. Managers, clinician and other members of the treating team share the common goal of optimising patient care. Managers share accountability for the care delivered, the equitable use of resources and building a positive workplace culture.

The purpose of this guide is to provide clinicians with evidence-based strategies to support them to understand and fulfil their roles and responsibilities. It combines information from a range of existing guides and resources, including the National Safety and Quality Health Service Standards User Guide for Medication Management in Cancer Care.

This User Guide describes best practice strategies under each of the 28 specific actions to support organisations to deliver effective medication management in cancer services.

The Board established the Audit and Risk Committee in compliance with section 45 of the PGPA Act and section 17 of the Public Governance, Performance and Accountability Rule. Its primary role is to assist the Board to discharge its responsibilities in respect of financial reporting, performance reporting, risk oversight and management, internal control and compliance with relevant laws and policies.

This report describes the findings of a national stocktake of health resources developed for Aboriginal and Torres Strait Islander peoples, undertaken by the Cultural and Indigenous Research Centre Australia (CIRCA).

In 2019, Professor Lynne Emmerton led the review of name similarity for:

• Monoclonal antibodies (MABs) (commonly ending in the suffix ‘mab’)
• Tyrosine kinase (factor) inhibitors (TKIs) (commonly ending in the suffix ‘nib’).

This included the theoretical risk of confusion within these classes of medicines in clinical practice, including the similarity in clinical indication, with a view to producing a specialised list of medicines. The results of this review can be found in this publication.